This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, Z.-T. Articles by Wu, X.-R. Search for Related Content PubMed PubMed Citation Articles by Zhang, Z.-T. Articles by Wu, X.-R.

Urothelium-specific Expression of an Oncogene in Transgenic Mice Induced the Formation of Carcinoma in Situ and Invasive Transitional Cell Carcinoma¹

Departments of Urology [Z-T. Z., E. S., T-T. S., X-R. W.], Microbiology [X-R. W.], Dermatology [T-T. S.], and Pharmacology [T-T. S.], Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, New York 10016, and Department of Veterans Affairs Medical Center, Manhattan, New York, New York 10010 [J. P., X-R. W.]

Although many genetic alterations are known to be associated with human transitional cell carcinoma (TCC) of the urinary bladder, relatively little is known about the roles of these molecular defects, singular or in combination, in bladder tumorigenesis. We have developed a transgenic mouse model of bladder tumorigenesis using a 3.6-kb promoter of uroplakin II gene to drive the urothelium-specific expression of oncogenes. In this study, we demonstrate that transgenic mice bearing a low copy number of SV40T transgene developed bladder carcinoma in situ (CIS), whereas those bearing high copies developed CIS as well as invasive and metastatic TCCs. These results indicate that the SV40T inactivation of p53 and retinoblastoma gene products, defects frequently found in human bladder CIS and invasive TCCs, can cause the aggressive form of TCC. Our results also provide experimental proof that CIS is a precursor of invasive TCCs, thus supporting the concept of two distinct pathways of bladder tumorigenesis (papillary versus CIS/invasive TCC). This transgenic system can be used for the systematic dissection of the roles of individual or combinations of specific molecular events in bladder tumorigenesis.

This article has been cited by other articles:

				B. A. Hadaschik, H. Adomat, L. Fazli, Y. Fradet, R. J. Andersen, M. E. Gleave, and A. I. So Intravesical Chemotherapy of High-Grade Bladder Cancer with HTI-286, A Synthetic Analogue of the Marine Sponge Product Hemiasterlin Clin. Cancer Res., March 1, 2008; 14(5): 1510 - 1518. [Abstract] [Full Text] [PDF]

				J. A. Karam, S. F. Shariat, H.-Y. Huang, R.-C. Pong, R. Ashfaq, E. Shapiro, Y. Lotan, A. I. Sagalowsky, X.-R. Wu, and J.-T. Hsieh Decreased DOC-2/DAB2 Expression in Urothelial Carcinoma of the Bladder Clin. Cancer Res., August 1, 2007; 13(15): 4400 - 4406. [Abstract] [Full Text] [PDF]

				W. Liu, D. P. Evanoff, X. Chen, and Y. Luo Urinary Bladder Epithelium Antigen Induces CD8+ T Cell Tolerance, Activation, and Autoimmune Response J. Immunol., January 1, 2007; 178(1): 539 - 546. [Abstract] [Full Text] [PDF]

				M. Shrader, M. S. Pino, G. Brown, P. Black, L. Adam, M. Bar-Eli, C. P.N. Dinney, and D. J. McConkey Molecular correlates of gefitinib responsiveness in human bladder cancer cells Mol. Cancer Ther., January 1, 2007; 6(1): 277 - 285. [Abstract] [Full Text] [PDF]

				H. Tsuruta, H. Kishimoto, T. Sasaki, Y. Horie, M. Natsui, Y. Shibata, K. Hamada, N. Yajima, K. Kawahara, M. Sasaki, et al. Hyperplasia and Carcinomas in Pten-Deficient Mice and Reduced PTEN Protein in Human Bladder Cancer Patients. Cancer Res., September 1, 2006; 66(17): 8389 - 8396. [Abstract] [Full Text] [PDF]

				R.A. Crallan, N.T. Georgopoulos, and J. Southgate Experimental models of human bladder carcinogenesis Carcinogenesis, March 1, 2006; 27(3): 374 - 381. [Abstract] [Full Text] [PDF]

				F.-X. Liang, M. C. Bosland, H. Huang, R. Romih, S. Baptiste, F.-M. Deng, X.-R. Wu, E. Shapiro, and T.-T. Sun Cellular basis of urothelial squamous metaplasia: roles of lineage heterogeneity and cell replacement J. Cell Biol., December 5, 2005; 171(5): 835 - 844. [Abstract] [Full Text] [PDF]

				L. Mo, J. Cheng, E. Y.-H. P. Lee, T.-T. Sun, and X.-R. Wu Gene deletion in urothelium by specific expression of Cre recombinase Am J Physiol Renal Physiol, September 1, 2005; 289(3): F562 - F568. [Abstract] [Full Text] [PDF]

				A. Garcia-Espana, E. Salazar, T.-T. Sun, X.-R. Wu, and A. Pellicer Differential Expression of Cell Cycle Regulators in Phenotypic Variants of Transgenically Induced Bladder Tumors: Implications for Tumor Behavior Cancer Res., February 15, 2005; 65(4): 1150 - 1157. [Abstract] [Full Text] [PDF]

				L. Dyrskjot, M. Kruhoffer, T. Thykjaer, N. Marcussen, J. L. Jensen, K. Moller, and T. F. Orntoft Gene Expression in the Urinary Bladder: A Common Carcinoma in Situ Gene Expression Signature Exists Disregarding Histopathological Classification Cancer Res., June 1, 2004; 64(11): 4040 - 4048. [Abstract] [Full Text] [PDF]

				J. Cheng, H. Huang, J. Pak, E. Shapiro, T.-T. Sun, C. Cordon-Cardo, F. M. Waldman, and X.-R. Wu Allelic Loss of p53 Gene Is Associated with Genesis and Maintenance, but not Invasion, of Mouse Carcinoma in Situ of the Bladder Cancer Res., January 1, 2003; 63(1): 179 - 185. [Abstract] [Full Text] [PDF]

				J. Cheng, H. Huang, Z.-T. Zhang, E. Shapiro, A. Pellicer, T.-T. Sun, and X.-R. Wu Overexpression of Epidermal Growth Factor Receptor in Urothelium Elicits Urothelial Hyperplasia and Promotes Bladder Tumor Growth Cancer Res., July 15, 2002; 62(14): 4157 - 4163. [Abstract] [Full Text] [PDF]

				P. J. Grippo and E. P. Sandgren Highly Invasive Transitional Cell Carcinoma of the Bladder in a Simian Virus 40 T-Antigen Transgenic Mouse Model Am. J. Pathol., September 1, 2000; 157(3): 805 - 813. [Abstract] [Full Text] [PDF]

				J. R. Saam and J. I. Gordon Inducible Gene Knockouts in the Small Intestinal and Colonic Epithelium J. Biol. Chem., December 31, 1999; 274(53): 38071 - 38082. [Abstract] [Full Text] [PDF]